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The sites of dog and cat bites are contaminated with bac-
teria of the canine and feline oral cavities. Anaerobic
bacteria have been believed to be involved in half of dog
bite infections and two-thirds of cat bite infections [1, 2]. In
medical care for animals, antimicrobial agents, given to
human cases, are also used. It is predicted that some
anaerobic bacteria derived from the animal’s oral cavity,
which are isolated from lesions, will be resistant to anti-
microbial agents used for treating human infections.
Therefore, antimicrobial chemotherapy taking this issue
into consideration is needed, but there have been no reports
discussing studies on the antibiograms of such isolates
from infections in Japan.
Selecting inappropriate antimicrobial agents may delay
the healing of bite infections and may even promote pro-
gression to chronic deep infections including osteomyelitis.
It is therefore necessary to collect specimens before the
start of empiric therapy, to perform bacterial examinations
including those for anaerobic bacteria, and to conﬁrm the
presence/absence of bacteria, which are barely predicted
from previously reported antibiograms.
Dog bite infection
Dog bites include crush, lacerating and puncture wounds. A
facultative bacteria, Pasteurella multocida, is important
causative bacteria of dog bite infections. Staphylococcus spp.
is also involved in these infections. Many anaerobic bacteria,
which comprise the bacterial ﬂora of the canine oral cavity,
are also isolated, and at least half of all strains isolated from
these types of infections are believed to be anaerobes.
Goldstein et al. [1] reported isolation of: Fusobacterium spp.
(F. nucleatum, F. russii, F. canifelium, etc.), Prevotella spp.
(P. melaninogenica, P. intermedia, P. heparinolytica, P.
zoogleoformans, etc.), Porphyromonas spp. (P. macacae,
P. cansulci, P. gulae, P. canoris, P. circumdentaria, P. levii-
like, etc.), Bacteroides tectus, B. pyogenes, B. ureolyticus,
Tannerella forthythensis, anaerobic gram-positive cocci,
Propionibacterium spp., and other gram-positive bacilli.
On the other hand, anaerobic bacteria isolated from the
canine periodontal pocket reportedly include Prophyro-
monas salivosa, P. denticanis, P. gulae, P. cansulci,
P. endodontalis, P. canis, Bacteroides denticanium,
Tannerella forsythensis, Rikenella microfusus, anaerobic
gram-positive cocci, P. levii, P. cangingivalis, P. canoris,
and Campylobacter curvus, etc. Many bacterial species
characteristic of dogs, which are not isolated in humans,
are included among these anaerobic bacteria [3]. Antimi-
crobial agents used for human infections are also used for
treating pets. Because of this situation, there is also a
possibility of some of these bacteria showing drug resis-
tance. However, there have been no or only few studies on
the antibiograms of canine bacterial strains.
Cat bite infection
Cat bites include deep puncture wounds and scratches, and
two-thirds of the isolates from the infected wounds are also
anaerobic bacteria. Wounds of the hand or ﬁngers at sites
near tendons and bones are serious. Inappropriate treatment
may lead to functional insufﬁciency. Bacterial species,
which are isolated from human endogenous infections at an
extremely low frequency, for example, Porphyromonas
spp. speciﬁc to animals, which includes Prevotella hepa-
rinolytica, Bacteroides pyogenes and Bacteroides tectus,
etc. are reportedly isolated from cat bite infections. These
123
J Infect Chemother (2011) 17 (Suppl 1):77–79
DOI 10.1007/s10156-010-0144-7
. Open access under the Elsevier OA license.
species are not included in the database of the kit for
identifying anaerobic bacteria. It is therefore highly prob-
able that they are erroneously identiﬁed as different bac-
terial species. In a manner similar to that for dog bite
infections, the antibiograms of these isolates has not yet
been clariﬁed.
Human bite infection
Human bite infections or those involving complex wounds
such as those of the ﬁngers, which develop as a result of a
strong blow to the human face, are infections likely to
develop due to bacteria (including anaerobic bacteria)
comprising the ﬂora of the human oral cavity, as well as
resident ﬂora of the skin, which includes Staphylococcus
spp. Bite infections are among those with marked anaerobic
bacterial involvement. The following facultative bacteria are
isolated from infected wounds: Eikenella corrodens, Cap-
nocytophaga spp., and various anaerobes (Prevotella spp.,
Fusobacterium spp., gram-positive cocci, and gram-positive
bacilli) [3].
Treatment
Surgical treatment is important for bite infections. As a
rule, debridement and repair of the damaged tissue are
essential. It depends on the severity, but the basic anti-
bacterial drugs are cephamycins, oxacephems, b-lactamase
inhibitor combination drugs, carbapenems, clindamycin
(CLDM) and minocycline (MINO) for intravenous injec-
tion (Table 1). With regard to CLDM, the number of
Bacteroides spp., which are resistant to CLDM, is
increasing. Therefore, CLDM administration should be
based on the results of drug sensitivity testing. MINO is an
extremely effective drug, because infections with multiple
bacteria including Rickettsia spp. are suspected in many
cases. However, attention should be paid to the presence of
resistant bacteria as well. In cases in which bite infections
can be treated by oral administration of drugs according to
certain symptoms, faropenem (FRPM) which has high
antimicrobial activity against anaerobic bacteria can also
be selected. Gatiﬂoxacin (GFLX) and moxiﬂoxacin
(MFLX), which have been recognized as speciﬁc anti-
anaerobic ﬂuoroquinolones in recent years, can also be
used to treat bite infections.
Information about the existence of b-lactamase-pro-
ducing bacterial species in Prevotella spp. residing in the
human oral cavity has been collected. Therefore, when
using b-lactams, it is necessary to select antimicrobial
agents taking the following into consideration: b-lactamase
inhibitor combination drugs [sulbactam/ampicillin (SBT/
ABPC), sulbactam/cefoperazone (SBT/CPZ), tazobactam/
piperacillin (TAZ/PIPC)]; b-lactams that are resistant to
b-lactamase production by Prevotella spp. [cefmetazole
(CMZ), ﬂomoxef (FMOX), latamoxef (LMOX)], etc. It is
highly probable that b-lactamase-producing strains, like
isolates from the human oral cavity, are present in Prevo-
tella spp. among the anaerobic bacteria isolated from such
bite infections.
Consideration of Pasterella multocida, i.e., a facultative
bacterium (known to be the main causative microorganism
of certain infections), is needed when treating infections
developing after animal bites. P. multocida is highly sen-
sitive to benzyl penicillin (PCG). However, attention
should be paid to this bacterial resistance to vancomycin
(VCM) (used for treatment of MRSA) and to CLDM (used
for treatment of anaerobic bacterial infections). P. multo-
cida is resistant to erythromycin (EM) as well.
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Table 1 Examples of antimicrobial agents selected for treatment of
bite infections
Drugs injected
intravenously
1. Cefmetazole at a dose of 1–2 g, 2–4 times/
day
2. Flomoxef at a dose of 1–2 g, 2–4 times/day
3. Sulbactam/ampicillin at a dose of 2.5 g, 2–4
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4. Sulbactam/cefoperazone at a dose of 1–2 g,
2–4 times/day
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11. Clindamycin at a dose of 300–600 mg, 2–4/
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Drugs administered
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1. Faropenem at a dose of 150–300 mg, 3/day
2. Gatiﬂoxacin at a dose of 100–200 mg, 2/day
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